Informação sobre produto
- Ubrelvy
- Spiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide, 1′,2′,5,7-tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxo-, (3′S)-
- (3′S)-1′,2′,5,7-Tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxospiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide
- MK 1602
Ubrogepant is a small-molecule drug that is used to treat migraine. It inhibits the activity of a receptor called CGRP, which is associated with the development of migraine headaches. Ubrogepant has been shown to be effective in treating chronic cough and has also been found to be safe for long-term use. The drug does not have significant toxicity or major side effects. Ubrogepant may increase the risk of bleeding and gastrointestinal disorders when used with nonsteroidal anti-inflammatory drugs (NSAIDs).
Propriedades químicas
Consulta técnica sobre: 3D-FU165699 Ubrogepant
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
